Susquehanna Fundamental Investments’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Susquehanna Fundamental Investments’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-48,008	Closed	-$645K	–	922
2023 Q1	$645K	Hold	48,008	–	–	0.02%	621
2022 Q4	$594K	Sell	48,008 -43,824	-48%	-$621K	0.01%	815
2022 Q3	$1.28M	Buy	+91,832	New	+$1.48M	0.02%	721
2022 Q1	$266K	Hold	16,350	–	–	0.01%	1292
2021 Q4	$266K	Sell	16,350 -47,729	-74%	-$805K	0.01%	1156
2021 Q3	$952K	Buy	64,079 +16,350	+34%	+$262K	0.02%	889
2021 Q2	$953K	Buy	+47,729	New	+$946K	0.02%	873

Other funds holding ICPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return

DCM

DG Capital Management New York $475M AUM 36.12% 1-Year Est. Return

Susquehanna Fundamental Investments's ICPT Position: Q2 2023 in Review

Susquehanna Fundamental Investments sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q2 2023, closing a stake of 48,008 shares — an estimated $645K sold.

Susquehanna Fundamental Investments first reported a position in ICPT in Q2 2021 and held it in 7 quarters. The position peaked at $1.28M in Q3 2022. 126 funds tracked by Wall St. Rank hold ICPT as of Q2 2023.

Susquehanna Fundamental Investments reported no remaining Intercept Pharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
Susquehanna Fundamental Investments sold 48,008 Intercept Pharmaceuticals, Inc. shares in Q2 2023, an estimated $645K.
Susquehanna Fundamental Investments first reported a position in Intercept Pharmaceuticals, Inc. in Q2 2021 and held it in 7 quarters.
Susquehanna Fundamental Investments's Intercept Pharmaceuticals, Inc. position peaked at $1.28M in Q3 2022.
126 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q2 2023.

Based on Susquehanna Fundamental Investments's 13F filing for Q2 2023, filed 11 Aug 2023.